Yvonne Full
Otfried Müller Str. 27
Tuebingen, BW 72076, Germany
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study.
Journal: Frontiers in pharmacology
Published: November 10, 2025
Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.
Journal: Frontiers in immunology
Published: May 20, 2025
MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection.
Journal: Frontiers in immunology
Published: December 23, 2023
Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA.
Journal: Nature biotechnology
Published: July 15, 2023
Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats.
Journal: Frontiers in pharmacology
Published: September 21, 2022
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans.
Journal: Frontiers in pharmacology
Published: March 13, 2022
ADAR1-mediated RNA editing promotes B cell lymphomagenesis.
Journal: iScience
Published: September 15, 2021
A conserved threonine in the S1-S2 loop of KV7.2 and K V7.3 channels regulates voltage-dependent activation.
Journal: Pflugers Archiv : European journal of physiology
Published: July 04, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026